Silence Therapeutics Q3 net loss narrows 41% to $12.43 million
SLN•Silence Therapeutics’ third-quarter 2026 net loss narrowed 41% year over year to $12.43 million, with no revenue recorded. Cash and cash equivalents totaled $247.7 million at September 30, and Merck KGaA’s acquisition of the business is expected to close in the first quarter of 2027, subject to customary conditions.
1. Quarterly results
Silence Therapeutics’ third-quarter 2026 net loss narrowed 41% year over year to $12.43 million. The company recorded no revenue, compared with $159,000 a year earlier. Research and development expenses fell 55% to $9.3 million, mainly due to completed zerlasiran Phase 3 readiness work and reduced personnel costs.
2. Cash and acquisition
Cash and cash equivalents totaled $247.7 million at September 30, including $201.3 million in gross proceeds from a public offering. Merck KGaA agreed to acquire the business, with closing expected in the first quarter of 2027, subject to customary conditions.
